Eiko Lifesciences approves 50:50 compressed biogas venture

Eiko Lifesciences Limited approved a 50:50 joint venture for compressed biogas production and distribution on 5 November 2026, with its wholly owned subsidiary participating in the proposed company. Eiko Lifesciences reported consolidated revenue from operations of Rs 17.72 crore for the quarter ended 30 September 2026, compared with Rs 11.67 crore a year earlier.

What did Eiko Lifesciences approve on 5 November 2026?

Eiko Lifesciences approved an investment by Eiko Scientific Solutions LLP to form Oval Eiko Resources Private Limited with Oval Projects Engineering Limited as a 50:50 joint venture. The board took the decision at its 5 November 2026 meeting, held from 3:30 pm to 4:00 pm, alongside approval of unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026.

Eiko Scientific Solutions LLP is a wholly owned subsidiary of Eiko Lifesciences, with 99.99% held by Eiko Lifesciences and 0.01% held by its nominee. The filing therefore places Eiko Lifesciences' participation in the proposed entity through the LLP rather than through a direct subscription by the listed company.

The proposed company received name approval from the Ministry of Corporate Affairs on 23 October 2026 and is intended to be incorporated in India. The company had not been incorporated at the time of the 5 November disclosure, which describes it as a proposed company.

The transaction introduces a disclosed renewable-energy activity alongside Eiko Lifesciences' existing reported operations. The standalone accounts identify speciality and fine chemicals as the sole business segment, while the consolidated accounts report speciality chemicals and pharma intermediates and logistics services as the two operating segments.

What business will the Eiko Lifesciences joint venture conduct?

The proposed Eiko Lifesciences joint venture will operate in renewable energy through compressed biogas production and distribution. The filing also lists a condensation stabilisation unit or industrial fuel and chemical unit, an essential-oil unit and an engineered-wood unit among Oval Eiko Resources' broad business activities.

Eiko Lifesciences did not disclose a production facility location, compressed-biogas capacity, commissioning date, feedstock arrangement, customer contract or projected revenue. The transaction disclosure states that no government or regulatory approval is required for the acquisition or formation, but it does not provide a separate timetable for any project-level permissions.

Cash is the stated form of consideration, and the filing gives initial proposed capital of Rs 2.50 lakh. It says Eiko Scientific Solutions LLP will subscribe for 50% of the total share capital through 25,000 equity shares with a face value of Rs 10 each.

The stated 25,000-share subscription amounts to Rs 2.50 lakh, equal to the disclosed initial proposed capital, although the filing also describes the LLP's interest as 50%. Eiko Lifesciences has not explained the final allocation of shares to Oval Projects Engineering or reconciled the stated capital and subscription details, leaving the completed capital structure to be confirmed on incorporation.

How did Eiko Lifesciences perform in the September 2026 quarter?

Eiko Lifesciences reported consolidated revenue from operations of Rs 17.72 crore in the quarter ended 30 September 2026, up from Rs 11.67 crore in the corresponding 2025 quarter and Rs 16.75 crore in the preceding June 2026 quarter. Consolidated net profit after tax was Rs 1.56 crore, compared with Rs 1.28 crore a year earlier and Rs 1.51 crore in the June quarter.

Speciality chemicals and pharma intermediates generated Rs 16.30 crore of quarterly revenue, compared with Rs 10.25 crore a year earlier. Logistics services generated Rs 1.42 crore, unchanged from the September 2025 quarter, so the year-on-year increase in consolidated revenue primarily reflected the chemicals and pharma-intermediates segment.

For the half year ended 30 September 2026, Eiko Lifesciences reported consolidated revenue from operations of Rs 34.47 crore, versus Rs 22.38 crore in the corresponding prior-year half year. Profit before tax increased to Rs 4.06 crore from Rs 3.20 crore, and net profit after tax rose to Rs 3.07 crore from Rs 2.40 crore.

The quarterly consolidated result included Rs 2.06 crore of profit before tax, after finance cost of Rs 15.81 lakh and other income of Rs 22.61 lakh. The segment statement recorded speciality chemicals and pharma intermediates segment result of Rs 1.23 crore, while logistics services contributed Rs 31.20 lakh.

What do Eiko Lifesciences cash flows and balance sheet show?

Eiko Lifesciences ended 30 September 2026 with consolidated cash and cash equivalents of Rs 3.10 crore, down from Rs 13.61 crore at 31 March 2026. The six-month cash movement included Rs 2.22 crore of net cash used in operating activities, Rs 9.48 crore used in investing activities and Rs 1.19 crore generated from financing activities.

The operating cash outflow was recorded despite half-year consolidated profit before tax of Rs 4.06 crore. The cash-flow statement shows a Rs 4.48 crore decrease in trade and other payables and a Rs 2.80 crore increase in trade receivables, partly offset by a Rs 1.42 crore decrease in inventories.

Consolidated loans within non-current assets increased to Rs 14.98 crore at 30 September 2026 from Rs 4.57 crore at 31 March 2026. The investing cash-flow statement records Rs 10.41 crore used for deposits, loans and advances during the half year, while investments were Rs 15.35 crore at 30 September, compared with Rs 15.29 crore at the March year-end.

Total consolidated assets were Rs 88.52 crore at 30 September 2026, compared with Rs 89.37 crore at 31 March 2026. Non-current borrowings increased to Rs 3.27 crore from Rs 3.06 crore, while current borrowings declined by Rs 87.92 lakh to Rs 79.53 lakh over the same period.

Conclusion

Eiko Lifesciences has approved an indirect 50:50 entry into renewable energy through a proposed compressed-biogas business while its reported September-quarter growth was led by speciality chemicals and pharma intermediates. Consolidated revenue increased by Rs 6.05 crore year on year to Rs 17.72 crore, whereas logistics revenue remained at Rs 1.42 crore.

The next disclosed step is incorporation of Oval Eiko Resources after the 23 October 2026 name approval. The filing leaves the final share allocation and capitalisation to be clarified, particularly because it describes both a 50:50 venture and an LLP subscription of 25,000 shares worth Rs 2.50 lakh against initial proposed capital of Rs 2.50 lakh.